LV10262B - Process for producing pharmaceutical compounds - Google Patents

Process for producing pharmaceutical compounds

Info

Publication number
LV10262B
LV10262B LVP-93-517A LV930517A LV10262B LV 10262 B LV10262 B LV 10262B LV 930517 A LV930517 A LV 930517A LV 10262 B LV10262 B LV 10262B
Authority
LV
Latvia
Prior art keywords
pharmaceutical compounds
producing pharmaceutical
methyl
producing
thieno
Prior art date
Application number
LVP-93-517A
Other languages
English (en)
Other versions
LV10262A (lv
Inventor
Jiban Kumar Chakrabarti
Terrence Michael Hotten
David Edward Tupper
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10674942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV10262(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of LV10262A publication Critical patent/LV10262A/xx
Publication of LV10262B publication Critical patent/LV10262B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
LVP-93-517A 1990-04-25 1993-06-08 Process for producing pharmaceutical compounds LV10262B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909009229A GB9009229D0 (en) 1990-04-25 1990-04-25 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
LV10262A LV10262A (lv) 1994-10-20
LV10262B true LV10262B (en) 1995-04-20

Family

ID=10674942

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-517A LV10262B (en) 1990-04-25 1993-06-08 Process for producing pharmaceutical compounds

Country Status (33)

Country Link
EP (1) EP0454436B1 (xx)
JP (1) JP2527860B2 (xx)
KR (1) KR100195566B1 (xx)
CN (1) CN1028429C (xx)
AT (1) ATE127804T1 (xx)
AU (1) AU643267B2 (xx)
BG (1) BG61710B2 (xx)
CA (1) CA2041113C (xx)
CY (1) CY1900A (xx)
CZ (1) CZ279937B6 (xx)
DE (3) DE19675046I2 (xx)
DK (1) DK0454436T3 (xx)
ES (1) ES2078440T3 (xx)
FI (1) FI101379B (xx)
GB (1) GB9009229D0 (xx)
GE (1) GEP20032965B (xx)
GR (1) GR3017877T3 (xx)
HK (1) HK87596A (xx)
HU (2) HU212416B (xx)
IE (1) IE68401B1 (xx)
IL (2) IL97912A (xx)
LU (2) LU90009I2 (xx)
LV (1) LV10262B (xx)
MX (1) MX173791B (xx)
NL (2) NL970015I2 (xx)
NO (3) NO178766C (xx)
NZ (1) NZ237932A (xx)
PT (1) PT97446B (xx)
RU (1) RU2043992C1 (xx)
SI (1) SI9110739A (xx)
SK (1) SK279196B6 (xx)
YU (1) YU48049B (xx)
ZA (1) ZA913085B (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817657A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Psychoactive substance disorders
US5817656A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Mental disorders
US5817655A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5627178A (en) * 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US6034078A (en) * 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
TW268005B (xx) * 1992-05-29 1996-01-11 Lilly Industries Ltd
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EP0733368A1 (en) * 1995-03-24 1996-09-25 Eli Lilly And Company Granule fomulation for olanzapine
CN1131035C (zh) * 1995-05-30 2003-12-17 伊莱利利公司 治疗识别机能障碍的方法
JPH11506096A (ja) * 1995-05-30 1999-06-02 イーライ・リリー・アンド・カンパニー 認識機能不全を処置する方法
US6506746B2 (en) 1995-05-30 2003-01-14 Eli Lilly And Company Method for treating cognitive dysfunction
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
AU1335397A (en) * 1995-12-21 1997-07-17 Eli Lilly And Company Method for treating dermatitis
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
KR100516088B1 (ko) 1996-09-23 2005-09-22 일라이 릴리 앤드 캄파니 올란자핀 이수화물 d
US6271225B1 (en) * 1997-09-02 2001-08-07 Welfide Corporation Fused thiophene compounds and medicinal use thereof
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
TR200000812T2 (tr) * 1997-09-30 2001-07-23 Eli Lilly And Company 2-metil-tieno- benzodiazepin formülasyonu.
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
IL154688A0 (en) 2000-08-31 2003-09-17 Reddys Lab Ltd Dr Hydrates of olanzapine and processes for the preparation thereof
JP4530664B2 (ja) * 2001-12-24 2010-08-25 サン・ファーマシューティカル・インダストリーズ・リミテッド 2−メチル−4−(4−メチル−1−ピペラジニル)−10H−チエノ[2,3−b][1,5]ベンゾジアゼピンの結晶形I、この結晶形Iの製造方法、及び医薬組成物
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
SI1513846T1 (sl) * 2002-05-31 2011-11-30 Sandoz Ag Postopek za pripravo olanzapina form I
AU2003239967A1 (en) * 2002-06-05 2003-12-22 Ivax Corporation Compound for the treatment of cns disorders
PL199016B1 (pl) * 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
SI21303A (sl) 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
DE10301923B3 (de) * 2003-01-17 2004-09-16 Krka Tovarna Zdravil, D.D. Verfahren und Zwischenprodukte zur Herstellung von Olanzapin
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
DE602004014264D1 (de) 2003-12-22 2008-07-17 Teva Pharma Verfahren zur herstellung von olanzapin
EP1709053B1 (en) 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
WO2005070939A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. Synthesis of olanzapine and intermediates thereof
AR048272A1 (es) * 2004-03-18 2006-04-12 Lek Pharmaceuticals Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
SI21850A (sl) * 2004-07-28 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
PL198589B1 (pl) 2004-11-22 2008-06-30 Adamed Sp Z Oo Sposób wytwarzania N-demetyloolanzapiny
ATE511512T1 (de) 2005-01-05 2011-06-15 Lilly Co Eli Olanzapinpamoat-dihydrat
HUP0501046A2 (en) 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
CN100383144C (zh) * 2006-09-11 2008-04-23 杭州盛美医药科技开发有限公司 一种奥氮平的中间体及其制备与应用
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2593407A1 (en) 2007-06-22 2008-12-22 Apotex Pharmachem Inc. Improved processes for the synthesis of olanzapine
CN101168544B (zh) * 2007-11-16 2010-11-17 西南合成制药股份有限公司 奥氮平的制备工艺
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
CN102532158A (zh) * 2010-12-17 2012-07-04 北大方正集团有限公司 一种合成奥氮平的方法
EP2486913A1 (en) 2011-02-14 2012-08-15 Labtec GmbH Rapidly disintegrating oral film formulation for Olanzapin
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
CN102225941B (zh) * 2011-06-01 2013-11-27 宁波人健医药化工有限公司 抗精神病药奥氮平的制备方法
WO2013066280A1 (en) * 2011-10-31 2013-05-10 Mahmut Bilgic Water soluble antipsychotic formulations
JP5934004B2 (ja) * 2012-03-22 2016-06-15 株式会社トクヤマ 結晶構造を有する4−アミノ−2−メチル−10H−チエノ〔2,3−b〕〔1,5〕ベンゾジアゼピン塩酸塩水和物及びその製造方法
WO2014021803A1 (en) 2012-07-31 2014-02-06 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. Use of olanzapine in animals
EP2879519A1 (en) 2012-07-31 2015-06-10 Sanovel Hayvan Sagligi Ürünleri Sanayi ve Ticaret A.S. A method for increasing meat and milk production
JP6042153B2 (ja) * 2012-09-26 2016-12-14 株式会社トクヤマ オランザピンの製造方法
KR101641902B1 (ko) 2015-06-24 2016-07-22 주식회사 네이처센스 농업회사법인 스트레스의 완화용 조성물
CN106265541A (zh) * 2016-08-31 2017-01-04 安徽省润生医药股份有限公司 一种注射用奥氮平及其制备方法
CN111004210A (zh) * 2019-10-23 2020-04-14 中山大学 化合物单晶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US3953430A (en) * 1975-02-24 1976-04-27 American Cyanamid Company Substituted benzodiazepin-10-ones and method of use
GB1533236A (en) * 1975-11-24 1978-11-22 Lilly Industries Ltd Thieno(1,5)benzodiazepine intermediates
GB1577743A (en) * 1977-05-17 1980-10-29 Lilly Industries Ltd Benzodiazepine derivatives

Also Published As

Publication number Publication date
CA2041113C (en) 1998-07-14
IL97912A0 (en) 1992-06-21
AU7518691A (en) 1991-11-07
RU2043992C1 (ru) 1995-09-20
GB9009229D0 (en) 1990-06-20
BG61710B2 (bg) 1998-03-31
NO178766C (no) 1996-05-29
NL300078I1 (nl) 2002-03-01
CA2041113A1 (en) 1991-10-26
IE68401B1 (en) 1996-06-12
FI101379B1 (fi) 1998-06-15
HUT60503A (en) 1992-09-28
GR3017877T3 (en) 1996-01-31
LV10262A (lv) 1994-10-20
CS9101168A2 (en) 1991-12-17
KR100195566B1 (ko) 1999-06-15
DE19675046I2 (de) 2001-05-23
ES2078440T3 (es) 1995-12-16
SI9110739A (en) 1997-10-31
NL970015I1 (nl) 1997-06-02
YU48049B (sh) 1996-10-18
NO1997005I1 (no) 1997-05-12
AU643267B2 (en) 1993-11-11
NZ237932A (en) 1993-08-26
NO2001028I1 (no) 2002-01-28
NL970015I2 (nl) 1997-09-01
EP0454436B1 (en) 1995-09-13
HU212416B (en) 1996-06-28
NO911624L (no) 1991-10-28
CZ279937B6 (cs) 1995-09-13
YU73991A (sh) 1994-01-20
ATE127804T1 (de) 1995-09-15
JPH0789965A (ja) 1995-04-04
HU211575A9 (en) 1995-12-28
DE69112895T4 (de) 2009-11-12
DE69112895T2 (de) 1996-03-07
GEP20032965B (en) 2003-05-12
DE69112895D1 (de) 1995-10-19
DK0454436T3 (da) 1995-11-13
CN1056693A (zh) 1991-12-04
FI101379B (fi) 1998-06-15
PT97446B (pt) 1997-07-31
IL112575A0 (en) 1995-05-26
HU911372D0 (en) 1991-10-28
CY1900A (en) 1991-04-24
KR910018387A (ko) 1991-11-30
IE911348A1 (en) 1991-11-06
FI911986A (fi) 1991-10-26
SK279196B6 (sk) 1998-07-08
HK87596A (en) 1996-05-24
LU90009I2 (fr) 1997-01-31
ZA913085B (en) 1992-12-30
MX173791B (es) 1994-03-25
FI911986A0 (fi) 1991-04-24
IL97912A (en) 1995-10-31
PT97446A (pt) 1992-01-31
NO178766B (no) 1996-02-19
CN1028429C (zh) 1995-05-17
NO911624D0 (no) 1991-04-24
EP0454436A1 (en) 1991-10-30
JP2527860B2 (ja) 1996-08-28
LU90869I2 (fr) 2002-02-21
MX25502A (es) 1993-10-01

Similar Documents

Publication Publication Date Title
LV10262B (en) Process for producing pharmaceutical compounds
TW372872B (en) Thieno[1,5]benzodiazepine use
AU4856893A (en) 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo{2,3-b}heterocyclic -2-one useful in the treatment of cognitive disorders of man
ES2058029A1 (es) Proceso para la produccion de sales del acido clavulanico.
EP0383171A3 (en) 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
ZA924517B (en) Aminomethyl-substituted 2,3-dihydropyrano(2,3-b)pyridines,process for their preparation and their use in medicaments
HU9200400D0 (en) Cinurenic acid derivatives, process for producing them and pharmaceutical compositions containing them
CS53688A2 (en) Method of new substituted 3-phenyl-7h-thiazolo/3,2-b//1,2,4/triazine -7-ons production
HUT53905A (en) Process for producing pharmacologically active triazolopyridine compounds active on central nervous system and pharmaceutical compositions comprising same